John Marquardt focuses his practice on biotechnology and pharmaceutical patents. He has extensive experience in biochemistry and molecular pharmacology, including experience working with multiple blockbuster drugs.

John helps clients achieve their goals through patent prosecution, due-diligence, and litigation. He has performed and managed complex and extensive electronic discovery. John also conducts pre-suit investigations and provides freedom to operate and validity opinions.

Drawing on over fourteen years of experience in scientific research at MIT, Harvard University, and the NIH, John’s laboratory experience includes work in genetic and protein engineering, macromolecular structure determination using nuclear magnetic resonance (NMR) spectroscopy and x-Ray crystallography, and modern drug-design.

John works on subject matter including traditional small-molecule drugs, gene therapies, protein therapeutics, monoclonal antibody therapies, diagnostic methods, and devices. His extensive experience in biochemistry and molecular pharmacology includes methods in molecular and cellular biology, immunology, microbiology, biochemistry, genomics, computational biology, small molecule pharmaceuticals, and biopharmaceuticals.

John is a frequent commentator, speaker, and author on patent law, specifically in the area of biosimilars. He has also lectured on strategic considerations under the Biologics Price Competition and Innovation Act (BPCIA).

While in law school, John served as an intern to the Honorable Randall R. Rader, in the US Court of Appeals for the Federal Circuit.

John is based in Washington, DC.

  • Monsanto v. Syngenta (D. Del.) - Defended against claims of infringement relating to two United States Patents involving technology for creation of herbicide resistant plants. Second chaired depositions of fact and expert witnesses relating to calculation of damages.
  • Telcordia v. Cisco, Lucent and Alcatel (D. Del.) - Asserted three patents relating to telecommunications protocols against defendants. Managed extensive offensive and defensive electronic discovery.
  • Wyeth Effexor XR® Litigations - Asserted three patents in ANDA litigations relating to Effexor XR® against 14 defendants. Supervised three junior attorneys and three consultants in extensive offensive and defensive electronic discovery in litigation asserting three patents against defendants. Second chaired depositions of expert witnesses.
  • Prosecuted patent applications relating to novel pharmaceutical compositions and formulations. The compositions included novel families of small molecule therapeutics; protein based therapeutics, including monoclonal and therapeutic antibodies; and nucleotide based therapeutics, including RNAi, microRNA, antisense and nucleotide analogues.
  • Prosecuted applications relating to electrochemiluminescent diagnostic devices and reagents. The electrochemiluminescent assays included enzyme linked immunoassays. Managed three junior attorneys over the course of four years in prosecution applications relating to diagnostic devices and reagents employing Raman spectroscopic detection. These included enzyme conjugated immunoassays and labeled antibody assays employing novel chemistry and methods for detection.
  • Participated in Examiner interviews with the USPTO. Prepared materials for reexamination and patent opposition proceedings. Obtained patent term extensions and supplementary protection certificates extending patent term.
  • Performed extensive pre-litigation review of English and Japanese language documents, totaling more than 500,000 pages, relating to a drug with sales in excess of $2 billion per year in preparation for ANDA challenge.
  • Biotechnology Committee and Chemical Practice Group, American Intellectual Property Law Association (AIPLA)
  • Editorial board of mAbs - an international, peer-reviewed journal
Expand All

John Marquardt focuses his practice on biotechnology and pharmaceutical patents. He has extensive experience in biochemistry and molecular pharmacology, including experience working with multiple blockbuster drugs.

John helps clients achieve their goals through patent prosecution, due-diligence, and litigation. He has performed and managed complex and extensive electronic discovery. John also conducts pre-suit investigations and provides freedom to operate and validity opinions.

Drawing on over fourteen years of experience in scientific research at MIT, Harvard University, and the NIH, John’s laboratory experience includes work in genetic and protein engineering, macromolecular structure determination using nuclear magnetic resonance (NMR) spectroscopy and x-Ray crystallography, and modern drug-design.

John works on subject matter including traditional small-molecule drugs, gene therapies, protein therapeutics, monoclonal antibody therapies, diagnostic methods, and devices. His extensive experience in biochemistry and molecular pharmacology includes methods in molecular and cellular biology, immunology, microbiology, biochemistry, genomics, computational biology, small molecule pharmaceuticals, and biopharmaceuticals.

John is a frequent commentator, speaker, and author on patent law, specifically in the area of biosimilars. He has also lectured on strategic considerations under the Biologics Price Competition and Innovation Act (BPCIA).

While in law school, John served as an intern to the Honorable Randall R. Rader, in the US Court of Appeals for the Federal Circuit.

John is based in Washington, DC.

  • Monsanto v. Syngenta (D. Del.) - Defended against claims of infringement relating to two United States Patents involving technology for creation of herbicide resistant plants. Second chaired depositions of fact and expert witnesses relating to calculation of damages.
  • Telcordia v. Cisco, Lucent and Alcatel (D. Del.) - Asserted three patents relating to telecommunications protocols against defendants. Managed extensive offensive and defensive electronic discovery.
  • Wyeth Effexor XR® Litigations - Asserted three patents in ANDA litigations relating to Effexor XR® against 14 defendants. Supervised three junior attorneys and three consultants in extensive offensive and defensive electronic discovery in litigation asserting three patents against defendants. Second chaired depositions of expert witnesses.
  • Prosecuted patent applications relating to novel pharmaceutical compositions and formulations. The compositions included novel families of small molecule therapeutics; protein based therapeutics, including monoclonal and therapeutic antibodies; and nucleotide based therapeutics, including RNAi, microRNA, antisense and nucleotide analogues.
  • Prosecuted applications relating to electrochemiluminescent diagnostic devices and reagents. The electrochemiluminescent assays included enzyme linked immunoassays. Managed three junior attorneys over the course of four years in prosecution applications relating to diagnostic devices and reagents employing Raman spectroscopic detection. These included enzyme conjugated immunoassays and labeled antibody assays employing novel chemistry and methods for detection.
  • Participated in Examiner interviews with the USPTO. Prepared materials for reexamination and patent opposition proceedings. Obtained patent term extensions and supplementary protection certificates extending patent term.
  • Performed extensive pre-litigation review of English and Japanese language documents, totaling more than 500,000 pages, relating to a drug with sales in excess of $2 billion per year in preparation for ANDA challenge.
  • Biotechnology Committee and Chemical Practice Group, American Intellectual Property Law Association (AIPLA)
  • Editorial board of mAbs - an international, peer-reviewed journal